FI120237B - Pantropisk neurotrofin-polypeptid - Google Patents
Pantropisk neurotrofin-polypeptid Download PDFInfo
- Publication number
- FI120237B FI120237B FI964833A FI964833A FI120237B FI 120237 B FI120237 B FI 120237B FI 964833 A FI964833 A FI 964833A FI 964833 A FI964833 A FI 964833A FI 120237 B FI120237 B FI 120237B
- Authority
- FI
- Finland
- Prior art keywords
- hngf
- trka
- binding
- ngf
- neurotrophin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (17)
1. Pantropisk neurotrofin-polypeptid innehällande en human NT-3 (hNT-3) eller human NGF (hNGF) aminosyrasekvens där har substituerats en aminosyra i en aminosyraposition som motsvarar positionen D15 i NT3 eller positionen D16 i hNGF, kännetecknadav att substitutionen ästadkommer trkB-bindning vid vilken nämnda D15-substituerade pantropiska hNT3 binder sig till reseptorerna trkB och trkC samt nämnda D16-substituerade hNGF binder sig till reseptorn trkB och minst tvä andra neurotrofinreseptorer som valts bland reseptorerna trkA, trkC och gp75.
2. Polypeptid enligt patentkrav 1, känneteck-n a d av att nämnda substitution är en alaninrest.
3. Polypeptid enligt patentkrav 2, känneteck-n a d av att nämnda alaninrest är substituerad i den position som motsvarar positionen D15 i hNT3.
• 4. Polypeptid enligt patentkrav 3, känneteck-n a d av att nämnda substitutionsposition är D15A i hNT3. • · • · · • · · • · •j.
5. Polypeptid enligt patentkrav 3, känneteck . .·. n a d av att där vidare har substituerats de sex första ♦ · · .·.·. aminosyrorna med nägon av följande aminosyrasekvenser: (1) de • · · sex första aminosyrorna i NGF, (2) YAEHKS, (3) YASHPIF, (4) ... YAHPIF, (5) YASHPIS, (6) YAEHPIF och (7) YAQHPIF.
• · · • · · • · ’*:** 6. Polypeptid enligt patentkrav 2 där har substituerats en alaninrest i en position som motsvarar positionen D16 i hNGF, kännetecknadav att nämnda polypeptid binder sig 1. till reseptorerna trkB, trkA och gp75. • · ·«·
7. Polypeptid enligt patentkrav 6, känneteck-n a d av att nämnda substitutionsposition är D16A i hNGF.
8. Polypeptid enligt patentkrav 6, känneteck^ n a d av att där vidare finns en substitution i förvariabelt omräde 1 för aminosyrorna V18, V20 och G23 sarat minst en substitution i variabelt omräde 4 för aminosyrorna Y79, T81, H84, F86 eller K88 för att astadkomma trkC-bindningsaktivitet med vilken den substituerade D16A hNGF dessutom binder sig till reseptorn trkC.
9. Polypeptid enligt patentkrav 8, känneteck-n a d av att där finns en substitution i positionerna D16A, V18E, V20L, G23T, Y79Q, T81K, H84Q, F86Y och K88R.
10. Polypeptid enligt patentkrav 9, känneteck--n a d av att den är D16A, V18E, V20L, G23T, Y79Q, T81K, H84Q, F86Y, K88R NGF till sin uppbyggnad.
11. Polypeptid enligt patentkrav 6, känneteck-n a d av att där dessutom finns en substitution i aminosyrapositionerna E41, K57, D72 eller N77 för att astadkomma • · · • *: en dylik större trkA-bindningsaktivitet. ·· · • · · t · • ·
12. Polypeptid enligt nägot av de föregäende • · .:. patentkraven 1-11, kännetecknadav att den innehäller • ·· · . .·. en kovalent heterodimer eller en kovalent homodimer. • · · • · · ··· • · · • · ·
13. Isolerad nukleinsyra, kännetecknadav ... att den kodar en polypeptid enligt nägot av de föregäende • · · *·]/ patentkraven 1-12.
• · • · • · · . : 14. Expressionsvektor, kännetecknadav att ··· den innehäller nukleinsyran enligt patentkrav 13. • · · • · « • · • i
15. Vardcell, kännetecknadav att den innehäller nukleinsyran enligt patentkrav 13.
16. Forfarande för framställning av polypeptiden enligt nägot av de foregäende patentkraven 1 - 12, kannetec-k n a t av att vid förfarandet utsatts en värdcell innehällande en nukleinsyra som kodar nämnda polypeptid för forhällanden som expresserar nämnda polypeptid.
17. Farmaceutisk sammansättning innehällande polypeptiden enligt nägot av de foregäende patentkraven 1 -12 hopblandad med en farmaceutiskt acceptabel excipient. ·· · • · · • · • · ·· · • · · • · • · • · • * · • · · • · ··· ···♦ • · · • · · ··· ··· • · · » · · ··· • · · • · · • •t • · • · ··· • · · • · · ··· ··· • · • · ··· 1 • · • · • · ···
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25393794A | 1994-06-03 | 1994-06-03 | |
US25393794 | 1994-06-03 | ||
PCT/US1995/006918 WO1995033829A1 (en) | 1994-06-03 | 1995-06-01 | Pantropic neurotrophic factors |
US9506918 | 1995-06-01 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI964833A FI964833A (sv) | 1996-12-03 |
FI964833A0 FI964833A0 (sv) | 1996-12-03 |
FI120237B true FI120237B (sv) | 2009-08-14 |
Family
ID=22962278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI964833A FI120237B (sv) | 1994-06-03 | 1996-12-03 | Pantropisk neurotrofin-polypeptid |
Country Status (17)
Country | Link |
---|---|
US (6) | US5728803A (sv) |
EP (1) | EP0763107B1 (sv) |
JP (1) | JPH10501138A (sv) |
CN (1) | CN1159439C (sv) |
AT (1) | ATE280825T1 (sv) |
AU (1) | AU695144B2 (sv) |
BR (1) | BR9508019B1 (sv) |
CA (1) | CA2191064C (sv) |
DE (1) | DE69533698T2 (sv) |
ES (1) | ES2231786T3 (sv) |
FI (1) | FI120237B (sv) |
IL (1) | IL113983A0 (sv) |
MX (1) | MX9605971A (sv) |
NO (1) | NO317938B1 (sv) |
NZ (1) | NZ287762A (sv) |
PT (1) | PT763107E (sv) |
WO (1) | WO1995033829A1 (sv) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5728803A (en) * | 1994-06-03 | 1998-03-17 | Genentech, Inc. | Pantropic neurotrophic factors |
DE19637718A1 (de) | 1996-04-01 | 1997-10-02 | Boehringer Mannheim Gmbh | Rekombinante inaktive Core-Streptavidin Mutanten |
WO1998021234A2 (en) | 1996-11-15 | 1998-05-22 | Genentech, Inc. | Purification of neurotrophins |
US6391571B1 (en) | 1997-04-01 | 2002-05-21 | Roche Diagnostics Gmbh | Recombinant inactive avidin mutants |
US6365373B2 (en) | 1997-04-25 | 2002-04-02 | Genentech, Inc. | Nucleic acids encoding NGF variants |
EP0977860A1 (en) * | 1997-04-25 | 2000-02-09 | Genentech, Inc. | Ngf variants |
US7452863B1 (en) | 1997-04-29 | 2008-11-18 | Genentech, Inc. | NGF variants |
US6113947A (en) * | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US6663899B2 (en) | 1997-06-13 | 2003-12-16 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US20040120891A1 (en) * | 1998-12-21 | 2004-06-24 | Craig Hill | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
US6652864B1 (en) * | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
GB0024550D0 (sv) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
CA2448956C (en) * | 2001-05-30 | 2017-10-03 | Genentech, Inc. | Anti-ngf antibodies for the treatment of various disorders |
WO2004016167A1 (en) * | 2002-08-16 | 2004-02-26 | The General Hospital Corporation | Non-invasive functional imaging of peripheral nervous system activation in humans and animals |
WO2004056385A2 (en) | 2002-12-20 | 2004-07-08 | Neuronicon Aps | Modulation of activity of neurotrophins |
WO2006072005A2 (en) * | 2004-12-30 | 2006-07-06 | The Johns Hopkins University | Methods for high efficiency survival/proliferation of human embyonic stem cells and human embyro survival in culture |
PT2120997T (pt) * | 2006-12-21 | 2017-05-05 | H Lundbeck As | Modulação da atividade de proneurotrofinas |
WO2009062149A1 (en) * | 2007-11-08 | 2009-05-14 | Creighton University | Methods for maintaining inner ear neurons |
US8447409B2 (en) * | 2008-10-15 | 2013-05-21 | Cochlear Limited | Electroneural interface for a medical implant |
US8259461B2 (en) * | 2008-11-25 | 2012-09-04 | Micron Technology, Inc. | Apparatus for bypassing faulty connections |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9783602B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
WO2017157325A1 (zh) * | 2016-03-18 | 2017-09-21 | 舒泰神(北京)生物制药股份有限公司 | 神经生长因子融合蛋白、制备方法及其用途 |
CN112409471B (zh) * | 2016-04-13 | 2022-07-29 | 舒泰神(北京)生物制药股份有限公司 | 低痛神经生长因子突变体 |
CN110183536B (zh) * | 2018-02-22 | 2021-01-15 | 中国科学院遗传与发育生物学研究所 | 一种复合支架材料及其应用 |
EP3823674A4 (en) | 2018-07-18 | 2022-12-28 | Manzanita Pharmaceuticals, Inc. | CONJUGATES FOR DELIVERING AN ANTI-CANCER AGENT TO NERVE CELLS, METHODS OF USE AND METHODS OF PRODUCTION THEREOF |
CN110812532A (zh) * | 2019-08-20 | 2020-02-21 | 中山大学 | 一种靶向促进皮质脊髓束连接以修复脊髓损伤的组织工程支架的构建方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5169764A (en) * | 1990-08-08 | 1992-12-08 | Regeneron Pharmaceuticals, Inc. | Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras |
US5488099A (en) * | 1992-03-06 | 1996-01-30 | Persson, Deceased; Hakan B. | Multifunctional chimeric neurotrophic factors |
US5349055A (en) * | 1992-03-06 | 1994-09-20 | Persson Hakan B | Nerve growth factor having altered receptor binding specificities |
AU4535993A (en) * | 1992-06-12 | 1994-01-04 | Regeneron Pharmaceuticals, Inc. | Therapeutic and diagnostic methods based on neurotrophin-4 expression |
US5753225A (en) * | 1993-12-03 | 1998-05-19 | The Regents Of The University Of California | Antibodies that mimic actions of neurotrophins |
AU1282895A (en) * | 1993-12-29 | 1995-07-17 | Sumitomo Pharmaceuticals Company, Limited | Novel human ciliary neurotrophic factor |
US5728803A (en) * | 1994-06-03 | 1998-03-17 | Genentech, Inc. | Pantropic neurotrophic factors |
US7144983B1 (en) * | 1997-02-03 | 2006-12-05 | Genentech, Inc. | Pantropic neurotrophic factors |
-
1995
- 1995-05-12 US US08/440,049 patent/US5728803A/en not_active Expired - Lifetime
- 1995-05-15 US US08/441,513 patent/US5981480A/en not_active Expired - Lifetime
- 1995-06-01 ES ES95921550T patent/ES2231786T3/es not_active Expired - Lifetime
- 1995-06-01 DE DE69533698T patent/DE69533698T2/de not_active Expired - Lifetime
- 1995-06-01 NZ NZ287762A patent/NZ287762A/xx not_active IP Right Cessation
- 1995-06-01 EP EP95921550A patent/EP0763107B1/en not_active Expired - Lifetime
- 1995-06-01 CN CNB951933817A patent/CN1159439C/zh not_active Expired - Lifetime
- 1995-06-01 IL IL11398395A patent/IL113983A0/xx not_active IP Right Cessation
- 1995-06-01 MX MX9605971A patent/MX9605971A/es active IP Right Grant
- 1995-06-01 WO PCT/US1995/006918 patent/WO1995033829A1/en active IP Right Grant
- 1995-06-01 PT PT95921550T patent/PT763107E/pt unknown
- 1995-06-01 AU AU26592/95A patent/AU695144B2/en not_active Expired
- 1995-06-01 AT AT95921550T patent/ATE280825T1/de active
- 1995-06-01 BR BRPI9508019-8A patent/BR9508019B1/pt not_active IP Right Cessation
- 1995-06-01 CA CA002191064A patent/CA2191064C/en not_active Expired - Lifetime
- 1995-06-01 JP JP8501183A patent/JPH10501138A/ja active Pending
-
1996
- 1996-12-02 NO NO19965123A patent/NO317938B1/no not_active IP Right Cessation
- 1996-12-03 FI FI964833A patent/FI120237B/sv not_active IP Right Cessation
-
1997
- 1997-02-03 US US08/794,028 patent/US6503728B1/en not_active Expired - Fee Related
- 1997-04-25 US US08/845,541 patent/US6333310B1/en not_active Expired - Lifetime
-
2006
- 2006-05-30 US US11/443,576 patent/US7528233B2/en not_active Expired - Fee Related
-
2009
- 2009-03-10 US US12/401,483 patent/US7935671B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2191064A1 (en) | 1995-12-14 |
DE69533698T2 (de) | 2006-02-09 |
US6503728B1 (en) | 2003-01-07 |
AU695144B2 (en) | 1998-08-06 |
NO317938B1 (no) | 2005-01-10 |
JPH10501138A (ja) | 1998-02-03 |
BR9508019B1 (pt) | 2012-06-12 |
FI964833A (sv) | 1996-12-03 |
IL113983A0 (en) | 1995-10-31 |
FI964833A0 (sv) | 1996-12-03 |
ES2231786T3 (es) | 2005-05-16 |
DE69533698D1 (de) | 2004-12-02 |
PT763107E (pt) | 2005-02-28 |
BR9508019A (pt) | 1997-09-09 |
US5981480A (en) | 1999-11-09 |
NZ287762A (en) | 1999-01-28 |
US5728803A (en) | 1998-03-17 |
NO965123L (no) | 1997-02-03 |
CA2191064C (en) | 2009-11-03 |
EP0763107B1 (en) | 2004-10-27 |
CN1159439C (zh) | 2004-07-28 |
US7935671B2 (en) | 2011-05-03 |
AU2659295A (en) | 1996-01-04 |
US20060270838A1 (en) | 2006-11-30 |
MX9605971A (es) | 1997-12-31 |
US6333310B1 (en) | 2001-12-25 |
NO965123D0 (no) | 1996-12-02 |
US7528233B2 (en) | 2009-05-05 |
CN1153528A (zh) | 1997-07-02 |
WO1995033829A1 (en) | 1995-12-14 |
ATE280825T1 (de) | 2004-11-15 |
EP0763107A1 (en) | 1997-03-19 |
US20100184656A1 (en) | 2010-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI120237B (sv) | Pantropisk neurotrofin-polypeptid | |
Urfer et al. | The binding epitopes of neurotrophin‐3 to its receptors trkC and gp75 and the design of a multifunctional human neurotrophin. | |
Lai et al. | Cloning and expression of a novel neurotrophin, NT-7, from carp | |
US6365373B2 (en) | Nucleic acids encoding NGF variants | |
Lu | BDNF and activity-dependent synaptic modulation | |
Allendoerfer et al. | Regulation of neurotrophin receptors during the maturation of the mammalian visual system | |
Battleman et al. | HSV-1 vector-mediated gene transfer of the human nerve growth factor receptor p75hNGFR defines high-affinity NGF binding | |
Soppet et al. | The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor | |
Ebendal | Function and evolution in the NGF family and its receptors | |
US8101571B2 (en) | Treatment methods using NGF variants | |
Ibanez et al. | An extended surface of binding to Trk tyrosine kinase receptors in NGF and BDNF allows the engineering of a multifunctional pan‐neurotrophin. | |
Borasio et al. | ras p21 protein promotes survival and fiber outgrowth of cultured embryonic neurons | |
Feng et al. | Differential effects of GDNF and BDNF on cultured ventral mesencephalic neurons | |
Suter et al. | NGF/BDNF chimeric proteins: analysis of neurotrophin specificity by homolog-scanning mutagenesis | |
Allsopp et al. | Ectopic trkA expression mediates a NGF survival response in NGF-independent sensory neurons but not in parasympathetic neurons. | |
Escandon et al. | Characterization of neurotrophin receptors by affinity crosslinking | |
US7144983B1 (en) | Pantropic neurotrophic factors | |
EP0674660B1 (en) | Multifunctional neurotrophic factors | |
AU691915B2 (en) | Biologically active EPH family ligands | |
AU2002300365B2 (en) | NGF Variants | |
Kullander et al. | Specificity of neurotrophin‐3 determined by loss‐of‐function mutagenesis | |
Jaber et al. | Expression of polyadenylated and non-polyadenylated TrkC transcripts in the roent central nervous system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Ref document number: 120237 Country of ref document: FI |
|
MA | Patent expired |